ReviewThe Annals of pharmacotherapy2013
Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C.
Review in The Annals of pharmacotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04377451 (Metformin as Adjunctive Therapy in Overweight and Obese Patients With Dengue), which is not on this map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Metformin as Adjunctive Therapy in Overweight and Obese Patients With Dengue: an Open-label Safety and Tolerability Trial
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Association of preadmission metformin use and mortality in patients with sepsis and diabetes mellitus: a systematic review and meta-analysis of cohort studies.Critical care (London, England) · 2019 · on this mapPooled it
- Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma.Scientific reports · 2016Pooled it
- Research Progress on the Molecular Mechanism of Metformin Regulating AMPK Signaling Pathway in Inhibiting Liver Cancer.OncoTargets and therapy · 2026Review
- Association between metabolic associated fatty liver disease and HCC risk after SVR in HCV patients: A systematic review and meta-analysis.Clinical and experimental hepatology · 2025Article
- Metformin Inhibits Zika Virus Infection in Trophoblast Cell Line.Current microbiology · 2024Article
- Improved Tumor Response in Patients on Metformin Undergoing Yttrium-90 Radioembolization Segmentectomy for Hepatocellular Carcinoma.Cardiovascular and interventional radiology · 2021Article
- A geroscience perspective on immune resilience and infectious diseases: a potential case for metformin.GeroScience · 2021Review
- Metformin as adjunctive therapy for dengue in overweight and obese patients: a protocol for an open-label clinical trial (MeDO).Wellcome open research · 2020Article
- Does metformin exposure before ICU stay have any impact on patients' outcome? A retrospective cohort study of diabetic patients.Annals of intensive care · 2017Article
- Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus.Oncotarget · 2017Article
- Metformin promotes apoptosis in hepatocellular carcinoma through the CEBPD-induced autophagy pathway.Oncotarget · 2017Article
- Metformin and metabolic diseases: a focus on hepatic aspects.Frontiers of medicine · 2015Review
- Control of oxidative stress in hepatocellular carcinoma: Helpful or harmful?World journal of hepatology · 2015Review
- The influence of hypoglycemic drugs on exercise-mediated hypoglycemic effects in elderly type 2 diabetic patients.International journal of clinical and experimental medicine · 2015Article
- Efficacy of adding metformin to pegylated interferon and ribavirin in treatment naïve patients with chronic hepatitis C: a randomized double-blind controlled trial.Middle East journal of digestive diseases · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the safety and efficacy of metformin in patients with type 2 diabetes mellitus (T2DM) and chronic hepatitis C virus (HCV) with or without cirrhosis and hepatocellular carcinoma (HCC). DATA SOURCES: A PubMed (1946-August 2013) search using the keywords type 2 diabetes mellitus, metformin, hepatitis C virus, cirrhosis, and hepatocellular carcinoma was conducted. The references in published articles were reviewed to identify additional references for inclusion. STUDY SELECTION AND DATA EXTRACTION: Studies written in English, evaluating metformin use in human patients with T2DM and chronic HCV were included. DATA SYNTHESIS: Eight studies met criteria for inclusion. Two prospective, randomized controlled trials showed increased benefit with metformin on virological response in patients with insulin resistance receiving HCV treatment. A prospective observational study evaluated metformin exclusively in patients with T2DM and HCV and showed significant reductions in the occurrence of HCC, liver-related death, and liver transplant. Four retrospective case control studies showed a decreased risk of HCC with metformin treatment in patients with T2DM and chronic liver disease. Finally, a retrospective cohort study indicated an increased survival rate in patients with diabetes and HCC undergoing radiofrequency ablation. Although diarrhea was increased in patients receiving metformin, no serious adverse effects, including lactic acidosis, were reported.
conclusionsMetformin may provide benefit in the treatment of HCV and in reducing the risk of HCC in patients with T2DM and HCV. Further long-term, randomized controlled trials are needed to adequately assess the safety and efficacy of metformin therapy in patients with comorbid diabetes and chronic HCV.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.